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useful in developing guidance for
health departments seeking to deter-
mine whether and how to implement
syndromic surveillance.
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Staphylococcus
aureus and
Escherichia 
hermanii in
Diabetes Patient
To the Editor: Polymicrobial
invasive infections are infrequent,
representing <10% of the invasive
infections of known etiology (1).
They are often correlated with a pre-
disposing factor: immunodeficiency
(e.g., diabetes mellitus, malignancies,
extremes of age) or use of a central
catheter.  Escherichia hermanii is an
extremely rare etiologic agent for
invasive infections; only four cases
were published from 1980 to 2002.
We report the first case of double
invasive infection by E. hermanii and
Staphylococcus aureus and emphasize
the importance of screening of all the
septic foci for demonstrating a
polymicrobial invasive infection. 
In August 2000, a 54-year-old
comatose man was admitted to our
infectious diseases department with a
10-day history of fever. He had a
medical history of vertebral arthrosis
(lumbar laminectomy in 1989) and
insulin-dependent diabetes mellitus.
Six weeks before, he had received for
3 days gluteal injections with kebu-
sone (an intramuscular nonsteriodal
antiinflammatory drug [NSAID]) for
acute lower back pain. Twenty-eight
days after the first injection, a gluteal
abscess developed, which was surgi-
cally drained, without perioperative
antimicrobial therapy. Three days
later, he became febrile, and pyrexia
persisted despite local wound man-
agement and treatment with oxacillin,
4 g/day for 3 days; cefuroxime, 3
g/day, and gentamicin, 160 mg/day
for another 7 days.
The patient became comatose and
was transferred to our department. At
that time, the physical examination
showed fever (40.2°C), neck stiffness,
Brudzinski sign, thoracic dullness,
and bilateral crackling rales. The level
of C-reactive protein was 123 mg/L.
Renal failure was noted with a creati-
nine blood level of 312 mmol/L and
uncontrolled diabetes with fasting
glucose of 24.75 mmol/L. Computed
tomographic (CT) scan of the brain
did not show brain abscesses or
tumors. Examination of the cere-
brospinal fluid (CSF) indicated a pro-
tein level of 2.67 g/L, decreased glu-
cose concentration of 0.55 mmol/L,
and a leukocyte count of 2.3 x 109/L
with 96% neutrophils; no microbial
pathogens were demonstrable under
direct examination of CSF. Chest x-
ray identified bronchopneumonia and
bilateral pleural effusion. The pleural
fluid analysis revealed a purulent exu-
date—protein, 4.5 g/L—containing
55% neutrophils. A urine specimen
and three blood samples were
obtained for cultures over the first 4
hours after admission. A bacterial
invasive infection was considered and
the antibiotic therapy was started with
ceftriaxone, 2 g/day, and rifampin,
1,200 mg/day. Concomitantly, the
patient received colloids to reestablish
blood volume, intravenous dexam-
ethasone, 6 mg four times daily, to
diminish the cerebral edema; and fast-
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acting insulin to control hyper-
glycemia. 
On day 3, the urine and CSF cul-
tures were positive for E. hermanii,
and the pleural fluid and all three
blood cultures yielded methicillin-
susceptible S. aureus. The E. hermanii
strain produced a yellow pigment.
The drug susceptibility was assessed
by AtB Expression system
(BioMerieux, Marcy l’Etoile, France).
The  Staphylococcus strain was sus-
ceptible to oxacillin, cotrimoxazole,
tetracycline, and ciprofloxacin and
resistant only to penicillin. E. her-
manii is naturally resistant to
aminopenicillins and carbenicillin;
this strain was susceptible to third-
generation cephalosporins, carbapen-
ems, cotrimoxazole, and quinolones
and resistant to aminoglycosides. 
The patient’s clinical central nerv-
ous system status improved, and he
came out of the coma, but his temper-
ature remained >37.5°C. He started to
report lumbar pain. On day 5, the
antimicrobial regimen was switched
to meropenem. After 24 hours, the
patient became apyretic, and glucose
and creatinine levels were normal on
day 8. However, on day 10, fever,
inflammation of the right thumb, and
intensified lower back pain devel-
oped. The abdominal CT and bone
scintigraphy indicated abscess of the
psoas, L4-L5 spondylitis, and thumb
periostitis. Intravenous ciprofloxacin
was added, 400 mg twice daily, and
apyrexia occurred on day 14. On day
21, open surgery was performed, con-
sisting of drainage of the psoas
abscess and curettage of the L4-L5
disc. On day 30, clinical improvement
and C-reactive protein level of 4.2
mg/L, led to a change to oral antimi-
crobial agents: cotrimoxazole 2 g/day
and ciprofloxacin 1.5 g/day. This reg-
imen was continued for 2 months
while the patient was seen as an out-
patient. The patient remained afebrile
and inflammation-free for the entire
24-month followup period.
Polymicrobial invasive infections
represent a major therapeutic prob-
lem. However, they are infrequent:
only 3.2% of infectious endocarditis
(2) cases and 6.27% of 2,188 commu-
nity-acquired bacteremia cases (3)
were polymicrobial. Polymicrobial
infections and elevated bacteremia
levels are more frequently associated
with diabetes; 20%–35% of the skin
and soft tissue infections in persons
with diabetes are polymicrobial (4),
and 15.7%–20% of the community-
acquired bacteremia cases were regis-
tered in persons with diabetes (3,4).
The probable entry site for S. aureus
was cutaneous. Intramuscular
NSAIDs are known to cause aseptic
necrosis, predisposing the patient to
staphylococcal abscesses. Hyper-
glycemia itself is a risk factor for soft-
tissue infections. The role of perioper-
ative antimicrobial therapy in pre-
venting the dissemination of infection
from a surgically drained abscess is
controversial (5). E. hermanii usually
produces wound or gastrointestinal
tract infections; in our patient, E. her-
manii probably originated from the
skin or from the gastrointestinal tract
(6–9). E. hermanii could be involved
more frequently in polymicrobial
invasive infections; of E. hermanii
invasive infections noted in four pub-
lished reports, two were polymicro-
bial (6,7). 
Initial antimicrobial drug therapy
was established empirically for proba-
ble staphylococcal meningitis. The
ongoing fever and persistent metabol-
ic disturbances led to an escalation of
therapy. Some authors recommend
carbapenems as the initial regimen
against invasive methicillin-suscepti-
ble  S. aureus infections with
meningeal or bone involvement (10).
The patient’s lower back and the inva-
sive staphylococcal infection urged us
to consider septic bone involvement.
The imaging studies confirmed the
existence of vertebral osteomyelitis;
ciprofloxacin was used based on its
excellent bone diffusion and its in
vitro activity on the two isolated
strains. Surgical intervention eradicat-
ed of one of the septic foci and
decreased risk for spinal cord injury;
27 (47%) of the 58 patients with
spondylodiscitis who were treated
surgically had a better outcome than
the other patients with medical care
only (11). Control of the infection
allowed changing to an oral regimen
after 1 month. We selected cotrimoxa-
zole and ciprofloxacin for their in
vitro effectiveness against the two
pathogens. Although this agent is not
usually used to treat bone infection,
we used cotrimoxazole on the basis of
evidence provided by several commu-
nications that indicated a superior
efficiency to referential regimens
(12).
In conclusion, the identification of
all organisms involved in polymicro-
bial invasive infections may require
cultures of specimens from all acces-
sible septic foci. For E. hermanii, a
role of “associated” pathogen in a
polymicrobial invasive infection
could be considered. Medical therapy
alone could be insufficient, and the
combined therapy allowed for a suc-
cessful outcome in invasive infection
with lumbar spondilodiscitis. 
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Multiple rpoB
Mutants of
Mycobacterium
tuberculosis and
Second-order
Selection 
To the Editor: Rad and colleagues
recently described variation in some
genes involved in DNArepair (mutT2,
mutT4, ogt) in Mycobacterium tuber-
culosis strains of different genotypes
(1). This approach can also be used to
investigate developing rifampin
resistance in the context of emerging
mutator alleles. Resistance to
rifampin in M. tuberculosis strains is
usually caused by the point mutations
in the rpoB gene encoding the β-sub-
unit of the DNA-dependent RNA
polymerase, which is a target of the
drug. Although a single point muta-
tion is sufficient for developing
rifampin resistance, a number of arti-
cles (2,3) describe multiple rpoB
mutants for M. tuberculosis, i.e.,
rifampin-resistant strains harboring
mutations in different codons of rpoB.
Double, triple, and quadruple muta-
tions in M. tuberculosis clinical iso-
lates were reported in studies con-
ducted throughout the world (2,3).
Such emergence, albeit infrequent, of
M. tuberculosis rpoB multiple
mutants raises questions about their
biologic importance and underlying
mechanisms; answers to both remain
elusive.
I propose an explanation of these
observations in terms of second-order
selection of hypermutable (mutator)
alleles based on alterations in DNA
repair genes. Unlike that of other anti-
tuberculosis drugs, resistance to
rifampin is acquired in most M. tuber-
culosis isolates by altering a single
target molecule and offers the most
appropriate and straightforward
model to demonstrate possible hyper-
mutability in this species. In
mycobacteria, hypermutability was
demonstrated in vitro for M. smegma-
tis, a surrogate model for M. tubercu-
losis, as an increase in reversion
(mutant to wild-type) rate in rpoB526
or rpsL43 under counterselection by
streptomycin or rifampin, respectively
(4). A correlation between high muta-
tion rate and antimicrobial resistance
was reported for Pseudomonas aerug-
inosa isolates from lungs of cystic
fibrosis patients (5). The mutator P.
aeruginosa strains resulted from a
defective mismatch-repair system (5).
In  M. tuberculosis, mismatch-repair
genes (mutH, mutL, mutS, and recJ)
were not found in its genome (6).
However, the nucleotide pool in this
species is exceptionally clean because
of the presence of several copies of
the mutT gene (1,6); the MutT protein
removes oxidized guanines (8-Oxo-
dGTP), thus counteracting replication
or transcription errors. Consequently,
the MutHLS mismatch-repair system
simply may be not required in M.
tuberculosis (6). Therefore, hyper-
mutability in some strains of this
species resulting in multiple rpoB
mutants might develop under certain
special (in vivo) circumstances
through inactivation or down-regula-
tion of some mutT genes. Further, the
two most frequently described rpoB
mutations are 531TCG→TTG and
526CAC→TAC. Both are cytosine-
to-tymine transitions, which easily
occur by spontaneous cytosine deam-
ination to uracil. Indeed, M. tubercu-
losis is a G+C rich organism, there-
fore, it is naturally at high risk for
cytosine deamination. Furthermore,
pathogenic mycobacteria are at
increased risk for deamination
because of the production of reactive
oxygen and nitrogen intermediates
inside host macrophages. This deami-
nation process is normally counteract-
ed by uracil-N-glycosylase, the prod-
uct of the ung gene, and organisms
defective in the removal of uracil
from DNA have an increased sponta-
neous mutation rate and more
G:C→A:T base-pair transitions (7).
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